| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
94,542,000 |
| Market
Cap: |
1.87(B) |
| Last
Volume: |
884,098 |
Avg
Vol: |
691,753 |
| 52
Week Range: |
$13.91 - $23.73 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 618 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Myriad Genetics is precision medicine company acting as an advisor to transform patient lives through molecular diagnostics. Co.'s molecular diagnostic tests are designed to analyze genes, their expression levels and corresponding proteins to assess an individual's risk for developing disease later in life, diagnose disease, determine a patient's likelihood of responding to a particular drug, or disease recurrence and assess a patient's risk of disease progression. Co. also provides biomarker discovery and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries utilizing its multiplexed immunoassay technology.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
30,000 |
38,638 |
109,679 |
| Total Sell Value |
$0 |
$572,835 |
$771,595 |
$2,187,775 |
| Total People Sold |
0 |
1 |
2 |
3 |
| Total Sell Transactions |
0 |
1 |
2 |
9 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Haas Kevin Richard |
SVP Technology |
• – – |
2021-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
42,443 |
|
- |
|
| Lanchbury Jerry S |
Chief Scientific Officer |
• – – |
2021-02-16 |
4 |
AS |
$29.71 |
$2,377,048 |
D/D |
(80,000) |
246,575 |
|
9% |
|
| Lanchbury Jerry S |
Chief Scientific Officer |
• – – |
2021-02-16 |
4 |
OE |
$18.00 |
$1,440,000 |
D/D |
80,000 |
252,130 |
|
- |
|
| Parkinson Paul |
EVP Strategy and Innovation |
• – – |
2021-01-08 |
4 |
AS |
$25.00 |
$295,600 |
D/D |
(11,824) |
76,746 |
|
11% |
|
| Newcomer Lee Nisley |
Director |
– • – |
2020-12-04 |
4 |
A |
$0.00 |
$0 |
D/D |
15,889 |
27,576 |
|
- |
|
| Dreismann Heinrich |
Director |
– • – |
2020-12-04 |
4 |
A |
$0.00 |
$0 |
D/D |
15,889 |
70,679 |
|
- |
|
| Spiegelman Daniel K |
Director |
– • – |
2020-12-04 |
4 |
A |
$0.00 |
$0 |
D/D |
15,889 |
36,451 |
|
- |
|
| Langer Dennis |
Director |
– • – |
2020-12-04 |
4 |
A |
$0.00 |
$0 |
D/D |
15,889 |
76,679 |
|
- |
|
| Phanstiel S. Louise |
Director |
– • – |
2020-12-04 |
4 |
A |
$0.00 |
$0 |
D/D |
15,889 |
82,679 |
|
- |
|
| Skovronsky Daniel |
Director |
– • – |
2020-12-04 |
4 |
A |
$0.00 |
$0 |
D/D |
15,889 |
40,930 |
|
- |
|
| Reitan Colleen F |
Director |
– • – |
2020-12-04 |
4 |
A |
$0.00 |
$0 |
D/D |
15,889 |
27,576 |
|
- |
|
| Phanstiel S. Louise |
Director |
– • – |
2020-11-11 |
4 |
B |
$16.62 |
$249,336 |
D/D |
15,000 |
66,790 |
2.39 |
68% |
|
| Parkinson Paul |
EVP Strategy and Innovation |
• – – |
2020-10-31 |
4 |
D |
$12.43 |
$27,570 |
D/D |
(2,218) |
88,570 |
|
- |
|
| Hart Jayne B. |
Executive VP Human Resources |
• – – |
2020-10-08 |
4 |
A |
$0.00 |
$0 |
D/D |
17,853 |
66,802 |
|
- |
|
| Verratti Mark |
President Assurex Health Inc. |
• – – |
2020-10-08 |
4 |
A |
$0.00 |
$0 |
D/D |
31,258 |
141,689 |
|
- |
|
| Riggsbee Richard Bryan |
Chief Financial Officer |
• – – |
2020-10-08 |
4 |
A |
$0.00 |
$0 |
D/D |
44,954 |
318,326 |
|
- |
|
| Jackson Benjamin |
E.V.P., General Counsel |
• – – |
2020-10-08 |
4 |
A |
$0.00 |
$0 |
D/D |
29,784 |
88,150 |
|
- |
|
| Lambert Nicole |
President, MGL |
• – – |
2020-10-08 |
4 |
A |
$0.00 |
$0 |
D/D |
44,211 |
106,212 |
|
- |
|
| Lanchbury Jerry S |
Chief Scientific Officer |
• – – |
2020-10-08 |
4 |
A |
$0.00 |
$0 |
D/D |
39,196 |
246,575 |
|
- |
|
| Parkinson Paul |
EVP Strategy and Innovation |
• – – |
2020-10-08 |
4 |
A |
$0.00 |
$0 |
D/D |
21,730 |
90,788 |
|
- |
|
| Hart Jayne B. |
Executive VP Human Resources |
• – – |
2020-09-30 |
4 |
D |
$13.04 |
$28,923 |
D/D |
(2,218) |
48,949 |
|
- |
|
| Lambert Nicole |
President, MGL |
• – – |
2020-09-30 |
4 |
D |
$13.04 |
$7,707 |
D/D |
(591) |
62,001 |
|
- |
|
| Jackson Benjamin |
E.V.P., General Counsel |
• – – |
2020-09-30 |
4 |
D |
$13.04 |
$5,425 |
D/D |
(416) |
58,366 |
|
- |
|
| Ford Alexander |
Chief Operating Officer |
• – – |
2020-09-30 |
4 |
D |
$13.04 |
$86,755 |
D/D |
(6,653) |
169,040 |
|
- |
|
| Verratti Mark |
President Assurex Health Inc. |
• – – |
2020-09-30 |
4 |
D |
$13.04 |
$9,454 |
D/D |
(725) |
110,431 |
|
- |
|
1303 Records found
|
|
Page 12 of 53 |
|
|
0.19 (0.95%) 
